Ghent University Academic Bibliography

Advanced

The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study

Daphne Hompes, André D'Hoore, Eric Van Cutsem, Steffen Fieuws, Wim Ceelen UGent, Marc Peeters UGent, Kurt Van der Speeten, Claude Bertrand, Hugues Legendre and Joseph Kerger (2012) ANNALS OF SURGICAL ONCOLOGY. 19(7). p.2186-2194
abstract
Up to 25% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis (PC) as the only site of metastases. Complete cytoreductive surgery (CCRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) aims for locoregional disease control and long-term survival. Oxaliplatin is effective for treating advanced CRC. This study assesses the safety and efficacy of CCRS with HIPEC with oxaliplatin for patients with PC of CRC. A Belgian prospective multicenter registry was performed to monitor perioperative morbidity and assess mortality, disease-free survival (DFS), and overall survival (OS). Forty-eight consecutive patients underwent CCRS (R0/1) with HIPEC (male/female ratio 17/31, median age 60 years, range 24-76 years). Median PC index was 11 (range 1-22). Median operation time was 460 (range 125-840) min, with a median blood loss of 475 (range 2-6,000) ml. Thirty-day mortality was 0%. Complication rate (any grade) was 52.1%. Anastomotic leakage occurred in 10.4% of patients, bleeding in 6.3%, and bowel perforation in 2.1%. Median hospital stay was 20 (range 5-65) days. At median follow-up of 22.7 (range 3.2-55.7) months, OS was 97.9% [95% confidence interval (CI) 86.1-99.7] at 1 year and 88.7% (95% CI 73.6-95.4) at 2 years. DFS at 1 year was 65.8% (95% CI 52.3-76.2) and 45.5% (95% CI 34.3-55.9) at 2 years. Median time until recurrence was 19.8 months (95% CI 12-upper limit not defined). Only after dichotomizing PC index was a significant difference in OS found between low and high PC index. CCRS followed by HIPEC with oxaliplatin for PC from CRC can be implemented with acceptable morbidity. Long-term DFS and OS can be achieved in selected patients.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
HEPATIC RESECTION, SYSTEMIC CHEMOTHERAPY, 1ST-LINE TREATMENT, LONG-TERM SURVIVAL, RANDOMIZED-TRIAL, MITOMYCIN-C, FOLLOW-UP, PHARMACOKINETICS, METASTASES, MANAGEMENT
journal title
ANNALS OF SURGICAL ONCOLOGY
Ann. Surg. Oncol.
volume
19
issue
7
pages
2186 - 2194
Web of Science type
Article
Web of Science id
000305558000017
JCR category
SURGERY
JCR impact factor
4.12 (2012)
JCR rank
8/195 (2012)
JCR quartile
1 (2012)
ISSN
1068-9265
DOI
10.1245/s10434-012-2264-z
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
3226964
handle
http://hdl.handle.net/1854/LU-3226964
date created
2013-05-28 14:31:50
date last changed
2016-12-19 15:42:53
@article{3226964,
  abstract     = {Up to 25\% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis (PC) as the only site of metastases. Complete cytoreductive surgery (CCRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) aims for locoregional disease control and long-term survival. Oxaliplatin is effective for treating advanced CRC. This study assesses the safety and efficacy of CCRS with HIPEC with oxaliplatin for patients with PC of CRC. 
A Belgian prospective multicenter registry was performed to monitor perioperative morbidity and assess mortality, disease-free survival (DFS), and overall survival (OS). 
Forty-eight consecutive patients underwent CCRS (R0/1) with HIPEC (male/female ratio 17/31, median age 60 years, range 24-76 years). Median PC index was 11 (range 1-22). Median operation time was 460 (range 125-840) min, with a median blood loss of 475 (range 2-6,000) ml. Thirty-day mortality was 0\%. Complication rate (any grade) was 52.1\%. Anastomotic leakage occurred in 10.4\% of patients, bleeding in 6.3\%, and bowel perforation in 2.1\%. Median hospital stay was 20 (range 5-65) days. At median follow-up of 22.7 (range 3.2-55.7) months, OS was 97.9\% [95\% confidence interval (CI) 86.1-99.7] at 1 year and 88.7\% (95\% CI 73.6-95.4) at 2 years. DFS at 1 year was 65.8\% (95\% CI 52.3-76.2) and 45.5\% (95\% CI 34.3-55.9) at 2 years. Median time until recurrence was 19.8 months (95\% CI 12-upper limit not defined). Only after dichotomizing PC index was a significant difference in OS found between low and high PC index. 
CCRS followed by HIPEC with oxaliplatin for PC from CRC can be implemented with acceptable morbidity. Long-term DFS and OS can be achieved in selected patients.},
  author       = {Hompes, Daphne and D'Hoore, Andr{\'e} and Van Cutsem, Eric and Fieuws, Steffen and Ceelen, Wim and Peeters, Marc and Van der Speeten, Kurt and Bertrand, Claude and Legendre, Hugues and Kerger, Joseph},
  issn         = {1068-9265},
  journal      = {ANNALS OF SURGICAL ONCOLOGY},
  keyword      = {HEPATIC RESECTION,SYSTEMIC CHEMOTHERAPY,1ST-LINE TREATMENT,LONG-TERM SURVIVAL,RANDOMIZED-TRIAL,MITOMYCIN-C,FOLLOW-UP,PHARMACOKINETICS,METASTASES,MANAGEMENT},
  language     = {eng},
  number       = {7},
  pages        = {2186--2194},
  title        = {The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study},
  url          = {http://dx.doi.org/10.1245/s10434-012-2264-z},
  volume       = {19},
  year         = {2012},
}

Chicago
Hompes, Daphne, André D’Hoore, Eric Van Cutsem, Steffen Fieuws, Wim Ceelen, Marc Peeters, Kurt Van der Speeten, Claude Bertrand, Hugues Legendre, and Joseph Kerger. 2012. “The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: a Belgian Multicentre Prospective Phase II Clinical Study.” Annals of Surgical Oncology 19 (7): 2186–2194.
APA
Hompes, Daphne, D’Hoore, A., Van Cutsem, E., Fieuws, S., Ceelen, W., Peeters, M., Van der Speeten, K., et al. (2012). The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. ANNALS OF SURGICAL ONCOLOGY, 19(7), 2186–2194.
Vancouver
1.
Hompes D, D’Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M, et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. ANNALS OF SURGICAL ONCOLOGY. 2012;19(7):2186–94.
MLA
Hompes, Daphne, André D’Hoore, Eric Van Cutsem, et al. “The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: a Belgian Multicentre Prospective Phase II Clinical Study.” ANNALS OF SURGICAL ONCOLOGY 19.7 (2012): 2186–2194. Print.